Allergen immunotherapy in MASK-air users in real-life

Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies. To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air ® app: t...

Descripción completa

Detalles Bibliográficos
Autores: Sousa-Pinto, Bernardo|||0000-0002-1277-3401, Azevedo, Luís Filipe, Sá-Sousa, Ana, Vieira, Rafael José, Amaral, Rita, Klimek, Ludger|||0000-0001-9710-6685, Czarlewski, Wienczyslawa, Antó i Boqué, Josep Maria|||0000-0002-4736-8529, Bedbrook, Anna, Kvedariene, Violeta, Ventura, Maria Teresa, Ansotegui Zubeldia, Ignacio Javier|||0000-0002-6942-1511, Bergmann, Karl-Christian|||0000-0002-0306-9922, Brussino, Luisa|||0000-0001-7249-7616, Canonica, G. Walter|||0000-0001-8467-2557, Cardona, Victoria|||0000-0003-2197-9767, Carreiro-Martins, Pedro|||0000-0002-4129-133X, Casale, Thomas|||0000-0002-3149-7377, Cecchi, Lorenzo|||0000-0002-0658-2449, Chivato, Tomás, Chu, Derek K.|||0000-0001-8269-4496, Cingi, Cemal, Costa, Elisio M., Cruz, Alvaro A.|||0000-0002-7403-3871, De Feo, Giulia, Devillier, Philippe|||0000-0001-6054-1886, Fokkens, Wytske J., Gaga, Mina, Gemicioğlu, Bilun, Haahtela, Tari|||0000-0003-4757-2156, Ivancevich, Juan Carlos|||0000-0001-8713-6258, Ispayeva, Zhanat, Jutel, Marek, Kuna, Piotr, Kaidashev, Igor, Kraxner, Helga, Larenas-Linnemann, Désirée|||0000-0002-5713-5331, Laune, Daniel, Lipworth, Brian, Louis, Renaud, Makris, Michaël, Monti, Riccardo, Morais-Almeida, Mario|||0000-0003-1837-2980, Mösges, Ralph|||0000-0002-1928-810X, Mullol, Joaquim|||0000-0003-3463-5007, Odemyr, Mikaëla, Okamoto, Yoshitaka, Papadopoulos, Nikolaos G.|||0000-0002-4448-3468, Patella, Vincenzo|||0000-0001-5640-6446, Pham-Thi, Nhân, Regateiro, Frederico S., Reitsma, Sietze, Rouadi, Philip W.|||0000-0002-5365-9568, Samolinski, Boleslaw, Sova, Milan, Todo-Bom, Ana, Taborda-Barata, Luis, Tomazic, Peter Valentin, Toppila-Salmi, Sanna, Sastre, Joaquin|||0000-0003-4689-6837, Tsiligianni, Ioanna|||0000-0001-7922-7491, Valiulis, Arunas|||0000-0002-0287-9915, Wallace, Dana, Waserman, Susan, Yorgancioglu, Arzu, Zidarn, Mihaela|||0000-0003-0515-5207, Zuberbier, Torsten|||0000-0002-1466-8875, Fonseca, João Almeida, Bousquet, Jean|||0000-0002-4061-4766, Pfaar, Oliver|||0000-0003-4374-9639
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:292287
Acceso en línea:https://ddd.uab.cat/record/292287
https://dx.doi.org/urn:doi:10.1002/clt2.12128
Access Level:acceso abierto
Palabra clave:Allergic rhinitis
Immunotherapy
Mobile health
Patient-reported outcomes
Real-life data analysis
Descripción
Sumario:Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies. To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air ® app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT. We assessed the MASK-air ® data of European users with self-reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales-VASs), and a combined symptom-medication score (CSMS). We applied Bayesian mixed-effects models, with clustering by patient, country and pollen season. We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT-tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = -12.1;-2.8), lower VAS Work (average difference = 5.0; 95%CrI = -8.5;-1.5), and a lower CSMS (average difference = 3.7; 95%CrI = -9.3;2.2). When compared to SCIT, SLIT-tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = -17.2;-2.8), lower VAS Work (average difference = 7.8; 95%CrI = -15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = -18.5;0.2). In patients with grass pollen allergy, SLIT-tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally-harmonised standards for performing and reporting real-world data in AIT are needed to better understand its 'real-world' effectiveness.

Similares en LA Referencia